ENA-78 = Epithelial neutrophil-activating peptide-78; FKN = Fractalkine; FLT3 = FMS-related tyrosine kinase 3; G-CSF = Granulocyte colony-stimulating factor; PD-ECGF = Platelet-derived endothelial ...

"This study proposed a new paradigm for anti-angiogenic therapy and provided opportunity for developing new anti-angiogenic medication in the future," he says. Fuchs says researchers completed ...

Following anti-angiogenic therapy, tumors develop regions containing no blood vessels (green) and therefore no oxygen (red). The tumor cells are made visible by dyeing the nuclei blue. Disclaimer ...

The IMbrave 050 study, as the first global trial to explore the combination of antiangiogenic therapy and immunotherapy in the adjuvant setting for HCC, provides the most compelling evidence currently ...

Angiopoietin-2 (ANGPT2) is a ligand of the receptor tyrosine kinase TIE2 (TEK). In conjunction with vascular endothelial growth factor (VEGF), ANGPT2-TIE2 signaling induces vascular sprouting.